-
PNAS: Targeting SPOP proteins is expected to stop tau protein diseases, including Alzheimer's disease
Time of Update: 2023-02-03
Randall Eck, first author of the paper and a graduate student in neuroscience at the University of Washington School of Medicine, said, "When we eliminated the SPOP protein in this nematode model, we saw a dramatic reduction in tau accumulation and progressive nerve cell death, as well as improved behavioral deficits and lifespan.
-
Refresh your awareness! Tau actually protects neurons in Alzheimer's patients
Time of Update: 2023-02-03
*For medical professionals onlyNeurofibrillary tangles caused by excessive phosphorylation of tau protein are one of the two main pathological features of Alzheimer's disease (AD), so excessive tau pr
-
Alzheimer & Dementia: Head-to-head comparison of plasma and CSF biomarker, phosphorylated tau protein immunoassay, in memory clinics
Time of Update: 2023-01-04
References:Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays.
References:Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays.
References:Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays.
-
Nature sub-issue: "Someone else" that causes Alzheimer's disease tau neurotoxicity
Time of Update: 2022-11-26
Researchers from Indiana University School of Medicine have identified a protein that interacts and promotes the spread of the neurotoxic tau, which is mainly found in neurons that appear abnormal in the brains of Alzheimer's patients.
-
The onset of early Alzheimer's disease and tau pathology in the central region of the brain
Time of Update: 2022-11-14
Guide:Early onset of symptoms and disease progression in Alzheimer's disease (AD) are closely related to the spread of tau protein, but the underlying mechanism is unknown. Recently, a paper entitled
-
Alzheimer Dementia: Effects of intensive blood pressure reduction on plasma Aβ, neurofilament light chain and total tau in dementia in the SPRINT trial
Time of Update: 2022-09-06
references:Plasma amyloid beta, neurofilament light chain, and total tau in the Systolic Blood Pressure Intervention Trial (SPRINT) It has become a consensus that lowering blood pressure can reduce the risk of cardiovascular disease, but whether lower blood pressure is better, and what should be the ideal blood pressure lowering target?
-
Cell Post-translational modification profiles of human pathological tau proteins distinguish clinical stages of Alzheimer's disease
Time of Update: 2022-09-06
Proposed model of Tau fibrosis formation based on stoichiometric PTM analysisCollectively, this study provides an unprecedented quantitative and qualitative view of the molecular characterization of pathological Tau subtypes in human disease, which is critical for rational design of antibody and small molecule therapeutics and early clinical diagnosis .
-
JAMA Neurology: A clinical study of Tau-PET protein imaging for prediction of Alzheimer's disease based on biomarkers
Time of Update: 2022-09-06
AD: Alzheimer's diseaseAβ: β-amyloidA/T/NBiomarkers: Biomarkers associated with beta-amyloid deposition/pathological tau/neurodegenerationCU: Cognitive Impairment EBM: Event-Based ModelingMCI: Mild Cognitive ImpairmentPET: Positron Emission TomographySUVR: Normalized Uptake Value RatiobackgroundLongitudinal tau protein aggregation in the brain in different clinical stages of Alzheimer's disease (AD) is a research hotspot in the current field.
-
Differentiation of Traumatic Encephalopathy Syndrome (TES) from Alzheimer's Disease (AD) Based on Plasma p-Tau Measurements
Time of Update: 2022-08-30
This study measured plasma P-tau181 and P-tau217 (Meso Scale) in traumatic encephalopathy syndrome (TES), MCI/dementia patients (biomarkers identified as AD ("AD") and healthy controls ("HC") Discovery, MSD electrochemiluminescence) .
-
Alzheimer & Dementia: In addition to Aβ and tau, these plasma proteins are also associated with cognitive decline and dementia risk!
Time of Update: 2022-05-08
To this end, experts from the Department of Epidemiology and Public Health at UCL, UK, examined the association between 4,953 plasma proteins and the risk of cognitive decline and dementia in two cohort studies followed for 20 years.
-
Alzheimers Dementia: Inherited dementia with decreased nuclear integrity of the locus coeruleus followed by increased tau aggregation
Time of Update: 2022-04-23
In older adults, including preclinical sporadic AD, with specialized magnetic resonance imaging (MRI) methods, LC integrity peaks and begins to decline at age 54, which is the time in life when cortical tau begins to appear .
-
Alzheimer's: Amyloid and tau are a dangerous combination
Time of Update: 2022-04-22
Our current findings suggest that this may indeed contribute to memory function in the early stages of the disease," said brain researcher Emrah Düzel, an equine Spokesman for the DZNE website in the city of Gedeburg and director of the Institute for Cognitive Neurology and Dementia at Otter von Glick University in Magdeburg .
-
JNNP: Tau-PET imaging predicts cognitive decline and progression of brain atrophy in patients with early Alzheimer's disease
Time of Update: 2022-04-21
In the present study, we aimed to explore whether regional tau binding measured at baseline is associated with the rate of AD progression after 2 years of follow-up, based on (a) cognitive decline in specific cognitive domains and (b) regional The progression of brain atrophy was assessed .
-
NeuroImage: Deep learning maps large-scale histological tau proteins to validate neuroimaging biomarkers for Alzheimer's disease
Time of Update: 2022-02-19
IHCNet ArchitectureIHCNet ArchitectureThe study's artificial neural network estimated tau inclusions from brain images, with ROC AUCs of 0.
This study presents an end-to-end method to create terabyte-scale 3D tau content density maps and register them on MRI as a means to facilitate PET tracer validation .
-
dominant Alzheimer's disease with TAU as the target to evaluate the effect of exploratory treatment
Time of Update: 2021-12-31
As more and more clinical research evidence shows that targeting amyloid can reduce Alzheimer's disease (AD) biomarkers, the head of Tau NexGen clinical trials chose Eisai’s exploratory anti-amyloid β ( Aβ) fibrillary antibody lecanemab as a basic anti-amyloid drug .